3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Carcinoma, Renal Cell
24
Kidney Neoplasms
10
Neoplasms
9
Carcinoma
6
Colorectal Neoplasms
5
Carcinoma, Hepatocellular
5
Carcinoma, Non-Small-Cell Lung
4
Recurrence
3
Neoplasm Metastasis
3
Melanoma
3
Thyroid Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma
2
Lung Neoplasms
2
Kidney Diseases
2
Glioblastoma
2
Carcinoma, Adenoid Cystic
2
Breast Neoplasms
2
Advanced Solid Tumors
2
cT2a N0NxM0 Renal Tumor
1
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Solitary Fibrous Tumors
1
Solid Tumors
1
Solid Malignancies
1
Skin Neoplasms
1
Sarcoma, Alveolar Soft Part
1
Salivary Gland Neoplasms
1
Refractory or Recurrent Solid Tumors, Excluding CNS Tumors
1
Prostatic Neoplasms
1
Interventions
avelumab
2
Sunitinib
2
Nutrition Assessment
2
Blood Specimen Collection
2
Axitinib
2
trifluridine tipiracil drug combination
1
trebananib
1
spartalizumab
1
pembrolizumab
1
etelcalcetide hydrochloride
1
enzalutamide
1
bicalutamide
1
aldesleukin
1
Stents
1
Sorafenib
1
Sodium Bicarbonate
1
Resistance Training
1
Receptors, Androgen
1
Plasma Exchange
1
Pharmaceutical Preparations
1
Paclitaxel
1
Oxaliplatin
1
Nephrotomy
1
Nephrostomy, Percutaneous
1
Lysine Acetyltransferase 5
1
Leuprolide
1
Kidney Transplantation
1
Interleukin-2
1
Goserelin
1
Flutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
Kidney Diseases
×
Axitinib
×
Clear all
NCT02684006
2025-07-30
JAVELIN Renal 101
Pfizer
Phase 3
Completed
886 enrolled
37 charts
1 FDA
NCT02493751
2022-02-18
JAVELIN Renal 100
Pfizer
Phase 1
Completed
55 enrolled
27 charts